Literature DB >> 31410871

Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.

Jan Borysowski1,2, Hans-Jörg Ehni3, Andrzej Górski2,4.   

Abstract

Keywords:  evidence-based medicine; medication safety; pharmacotherapy; therapeutics

Mesh：

Year:  2019        PMID： 31410871      PMCID： PMC6783618          DOI： 10.1111/bcp.14068

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Off-label use of approved drugs: therapeutic opportunity and challenges.

Authors:  William M Bennett
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

Review 2.  Paediatric Drug Development and Formulation Design-a European Perspective.

Authors:  Diana A Van Riet-Nales; Piotr Kozarewicz; Brian Aylward; Rutger de Vries; Toine C G Egberts; Carin M A Rademaker; Alfred F A M Schobben
Journal:  AAPS PharmSciTech       Date:  2016-06-07       Impact factor: 3.246

Review 3.  Off-label use of drugs in children.

Authors:  Daniel A Frattarelli; Jeffrey L Galinkin; Thomas P Green; Timothy D Johnson; Kathleen A Neville; Ian M Paul; John N Van Den Anker
Journal:  Pediatrics       Date:  2014-02-24       Impact factor: 7.124

4.  Innovation and off-label use, the French case and more.

Authors:  Alain Braillon; Joel Lexchin
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

Review 5.  Ethics codes and use of new and innovative drugs.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

Review 6.  Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment.

Authors:  Joerg Albrecht; Adewole S Adamson; John S Barbieri; Daniel D Bennett; Elizabeth A Kiracofe; A Shadi Kourosh; Kieron S Leslie; Joseph F Merola; Josephine Nguyen; Elaine Siegfried; Nicole Strickland; Suzanne Olbricht; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2018-09-20       Impact factor: 11.527

Review 7.  Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials.

Authors:  Aviv Ladanie; John P A Ioannidis; Randall S Stafford; Hannah Ewald; Heiner C Bucher; Lars G Hemkens
Journal:  J Clin Epidemiol       Date:  2017-11-13       Impact factor: 6.437

8.  Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.

Authors:  Tewodros Eguale; David L Buckeridge; Aman Verma; Nancy E Winslade; Andrea Benedetti; James A Hanley; Robyn Tamblyn
Journal:  JAMA Intern Med       Date:  2016-01       Impact factor: 21.873

Review 9.  Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.

Authors:  Katlein França; Sergio Litewka
Journal:  Int J Dermatol       Date:  2018-08-31       Impact factor: 2.736
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.